Stocks
Mutual Funds
ETFs
Pro Tools
Terminal
WealthView
Pricing
Learn More
stocksCTLLAB
resources
CTLLAB

Clinitech Laboratory Ltd.

BSE: 544220
SME
Sector: Healthcare
Industry Group: Healthcare Services
41.50+1.5 (+3.75%)
20 Jul, 12:00 AM

Annual Reports and Financial Documents

Clinitech Laboratory Ltd. annual reports, quarterly results, earnings call transcripts and investor presentations. All official filings in one place.
202420252026
Annual Reports—FY 2025—
Quarterly Results
Conference Calls———
Presentations———

Corporate Announcements and Regulatory Filings

Clinitech Laboratory Ltd. BSE/NSE disclosures, board meeting outcomes, insider trading notifications, acquisitions and other regulatory filings.
  • Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 20187 Jul 2026
    Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
    Disclosure under REg 74(5) of SEBI (DP) Regulations for the quarter ended June 30, 2026
  • Reg. 32 (1), (3) - Statement of Deviation & Variation28 May 2026
    Statement Of Deviation & Variation As On March 31, 2026
    Statement disclosing no deviation and Variation from object of issue as on March 31, 2026
  • Outcome of Board Meeting28 May 2026
    Board Meeting Outcome for Outcome Of Board Meeting Held For FY 2026-27 Today I.E May 28, 2026 Through Video Conferencing At 02.30 P.M
    With reference to the above captioned subject, we wish to intimate your esteemed exchange that as decided in the Meeting of the Board of Directors of the Company held today, i.e., on May, ....
  • Board Meeting22 May 2026
    Board Meeting Intimation for Board Meeting For FY 2026-27 To Be Held On Thrusday, May 28, 2026 At 02.30 P.M Through Video Conferencing
    Clinitech Laboratory Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2026 ,inter alia, to consider and approve To consider and approve ....
  • Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A27 Apr 2026
    Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
    <b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
  • General25 Apr 2026
    General Update W.R.T Memorandum Of Understanding ("MOU")
    This is to inform that the company has entered into Memorandum Of Understanding ("MOU") dated 25th April, 2026 with M/s. MD Plus Multispeciality Clinic
  • General22 Apr 2026
    Non-Applicability Of Reg 23 Of SEBI (LODR) Regulations, 2015 W.R.T Related Party Transaction
    Undertaking for non-applicability of disclosure under Reg 23 of SEBI (LODR) Regulations, 2015 w.r.t related party transaction.
  • Reg.24(A)-Annual Secretarial Compliance15 Apr 2026
    Compliances-Reg.24(A)-Annual Secretarial Compliance
    Undertaking for non-applicablity of Annual Secretarial compliance report under Reg 24A of SEBI (LODR) since our company is SME listed entity.
  • General9 Apr 2026
    General Update Under Reg 30 Of SEBI (LODR) Regulations For Change In Market Maker
    General update under Reg 30 of SEBI (LODR) Regulations for change in market maker from SVCM Securities Private Limited to Kalpalabdhi Financials Private Limited w.e.f April 10, 2026 as ....
  • Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 20187 Apr 2026
    Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
    Certificate under REg 74(5) of SEBI (DP) Regulations for the quarter ended March 31, 2026.
  • General6 Apr 2026
    General Update W.R.T Receipt Of Letter From Promoter Under Reg 31(4) Of SEBI (SAST) Regulations For The Year Ended March 31, 2026
    General Update w.r.t to receipt of letter from promoter under Reg 31(4) of SEBI SAST regulations for the yera ended March 31, 2026
  • Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 201130 Mar 2026
    Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
    The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jagdish Nayak & PACs
  • Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 201130 Mar 2026
    Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
    The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Siddhesh Nayak & PACs
  • Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 201128 Mar 2026
    Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
    The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jagdish Umakant Nayak & PACs
  • Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 201127 Mar 2026
    Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
    The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Siddhesh Anant Nayak & PACs
  • Closure of Trading Window24 Mar 2026
    Closure of Trading Window
    Closure of Trading Window for Insiders of the company from Wednesday, April 01, 2026 for Audited Financial Results for the half year and year ended March 31, 2026. The Trading window will ....
  • Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 201120 Mar 2026
    Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
    The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jagdish Umakant Nayak & PACs
  • Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 201118 Mar 2026
    Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
    The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jagdish Umakant Nayak & PACs
  • Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 201114 Mar 2026
    Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
    The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jagdish Umakant Nayak
  • Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 201112 Mar 2026
    Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
    The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jagdish Umakant Nayak

Frequently Asked Questions

Where can I download the annual report of Clinitech Laboratory Ltd.?
Annual reports of Clinitech Laboratory Ltd. are available for download in the Annual Reports and Financial Documents section of the Resources tab, organised by financial year.
Where can I find the quarterly results of Clinitech Laboratory Ltd.?
Quarterly earnings results and presentations of Clinitech Laboratory Ltd. are available in the Annual Reports and Financial Documents section of the Resources tab. Detailed financials are also in the Statements tab.
Does Clinitech Laboratory Ltd. publish earnings call transcripts?
Earnings call transcripts of Clinitech Laboratory Ltd., where available, are listed in the Annual Reports and Financial Documents section of the Resources tab.
Where can I find investor presentations of Clinitech Laboratory Ltd.?
Investor presentations and annual day presentations of Clinitech Laboratory Ltd. are listed in the Resources tab under Annual Reports and Financial Documents.
What are the recent corporate announcements of Clinitech Laboratory Ltd.?
Corporate announcements and regulatory filings of Clinitech Laboratory Ltd. as submitted to BSE and NSE are available in the Corporate Announcements and Regulatory Filings section of the Resources tab.
How do I access the regulatory filings of Clinitech Laboratory Ltd.?
Regulatory filings including board meeting outcomes, insider trading disclosures and other exchange notifications of Clinitech Laboratory Ltd. are in the Corporate Announcements and Regulatory Filings section of the Resources tab.
What is the ISIN of Clinitech Laboratory Ltd.?
The ISIN (International Securities Identification Number) of Clinitech Laboratory Ltd. is INE0QMR01015. This is the unique identifier used across exchanges and depositories.
On which stock exchange is Clinitech Laboratory Ltd. listed?
Clinitech Laboratory Ltd. is listed on NSE and BSE. The NSE symbol is CTLLAB and the BSE code is -.
Where can I find the shareholding pattern of Clinitech Laboratory Ltd.?
The quarterly shareholding pattern of Clinitech Laboratory Ltd. showing promoter, FII, DII, mutual fund and public holdings is available in the Shareholding Pattern section on the Overview tab.
How current is the data for Clinitech Laboratory Ltd. on Sharpely?
Share price data for Clinitech Laboratory Ltd. is updated as of 20 Jul 2026. Financial statements, shareholding and other fundamental data are updated after each quarterly disclosure.